(Q34092454)

31 July 2017

2 references

25 April 2019

5 November 2020

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). (English)

1 reference

25136079

Kuhnt-Junius degeneration

31 July 2017

main subject

2 references

25 April 2019

5 November 2020

angiogenesis inhibitor

1 reference

5 November 2020

Ursula Schmidt-Erfurth

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Ngaihang Victor Chong

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Francesco Bandello

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

3

Anat Loewenstein

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

9

Gisbert Richard

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Reinier O Schlingemann

6

object named as

Reinier Schlingemann

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Jordi Monés i Carilla

8

object named as

Jordi Monés

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Michael Larsen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Eric Souied

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Bora Eldem

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

European Society of Retina Specialists

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

language of work or name

English

0 references

publication date

1 September 2014

3 references

British Journal of Ophthalmology

31 July 2017

25 April 2019

5 November 2020

3 references

25 April 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

5 November 2020

98

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

1144-1167

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial

4 June 2020

copyright license

2 references

25 April 2019

5 November 2020

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Anaphylaxis caused by intravenous fluorescein: clinical characteristics and review of literature

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Correlation of fundus fluorescein angiography and spectral-domain optical coherence tomography in identification of membrane subtypes in neovascular age-related macular degeneration.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

An epidemiological study of neovascular age-related macular degeneration in Germany

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Associations of candidate genes to age-related macular degeneration among racial/ethnic groups in the multi-ethnic study of atherosclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

The off-label use of medication: the latest on the Avastin - Lucentis debacle

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Detection of new-onset choroidal neovascularization

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Prevalence and risk factors for age-related macular degeneration in Indians: a comparative study in Singapore and India

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Evaluation of age-related macular degeneration with optical coherence tomography

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Retinal angiomatous proliferation in age–related macular degeneration. 2001.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Avastin doesn't blind people, people blind people

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Optical coherence tomography changes before the development of choroidal neovascularization in second eyes of patients with bilateral wet macular degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Treatment for submacular hemorrhage associated with neovascular age-related macular degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Medicare costs for neovascular age-related macular degeneration, 1994-2007.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Imaging in neovascular age-related macular degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Radiation treatment for age-related macular degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Radiation therapy for neovascular age-related macular degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Angiographic analysis of retinal-choroidal anastomosis by confocal scanning laser ophthalmoscopy technology and corresponding (eye-tracked) spectral-domain optical coherence tomography

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Relationship between angiographic and optical coherence tomographic (OCT) parameters for quantifying choroidal neovascular lesions

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Sensitivity advantage of swept source and Fourier domain optical coherence tomography

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Quantitative subanalysis of cystoid spaces and outer nuclear layer using optical coherence tomography in age-related macular degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Guidance for the treatment of neovascular age-related macular degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Targeting VEGF-A to treat cancer and age-related macular degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Ranibizumab for neovascular age-related macular degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Pars plana vitrectomy with peripheral retinotomy after injection of preoperative intravitreal tissue plasminogen activator: a modified procedure to drain massive subretinal haemorrhage

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Pegaptanib sodium for the treatment of neovascular age-related macular degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST report no. 12.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Prevalence of age-related macular degeneration in the United States

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

The biology of VEGF and its receptors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

VEGF-Trap: a VEGF blocker with potent antitumor effects

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynami

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Pathophysiology and management of subretinal hemorrhage

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Argon laser photocoagulation of subretinal neovascularization in senile macular degeneration. Results of a randomized study of 60 cases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Risk factors for age-related macular degeneration: Pooled findings from three continents.

5 July 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Reproducibility of fluorescein and indocyanine green angiographic assessment for RAP diagnosis: a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Correlation of high-definition optical coherence tomography and fluorescein angiography imaging in neovascular macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Aligning scan locations from consecutive spectral-domain optical coherence tomography examinations: a comparison among different strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Safety evaluation of repeated intravitreal injections of bevacizumab and ranibizumab in rabbit eyes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Predicted biological activity of intravitreal VEGF Trap.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Comparing protein VEGF inhibitors: In vitro biological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Surgical outcomes after massive subretinal hemorrhage secondary to age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer

28 October 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

Factors prognostic of visual outcome in patients with subretinal hemorrhage

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145443

ANTI-VEGF TREATMENT IN NEOVASCULAR AGE–RELATED MACULAR DEGENERATION

28 October 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305702

16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy for age-related macular degeneration: 12 month outcomes of a 'radiation-first' strategy

21 January 2018

1 reference

12 December 2020

Optical coherence tomography in ophthalmology: an overview

1 reference

12 December 2020

Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement

1 reference

12 December 2020

OPTIMIZING INDIVIDUALIZED THERAPY WITH BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

1 reference

12 December 2020

HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration

1 reference

12 December 2020

Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study

1 reference

12 December 2020

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

1 reference

12 December 2020

Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group

1 reference

12 December 2020

Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study

1 reference

12 December 2020

Vitreous surgery for hemorrhagic and fibrous complications of age-related macular degeneration

1 reference

12 December 2020

A prospective study of cigarette smoking and age-related macular degeneration in women

1 reference

12 December 2020

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study

1 reference

12 December 2020

Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections

1 reference

12 December 2020

Experimental subretinal hemorrhage in rabbits

1 reference

12 December 2020

Surgical management of submacular hemorrhage. A series of 47 consecutive cases

1 reference

12 December 2020

Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio

1 reference

12 December 2020

Angiographic regression patterns after intravitreal ranibizumab injections for neovascular age-related macular degeneration

1 reference

12 December 2020

Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab

1 reference

12 December 2020

Management of submacular hemorrhage with intravitreal injection of tissue plasminogen activator and expansile gas

1 reference

12 December 2020

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1

1 reference

12 December 2020

Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator

1 reference

12 December 2020

Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration

1 reference

12 December 2020

Tissue plasminogen activating factor assisted removal of subretinal hemorrhage

1 reference

12 December 2020

Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Macular Photocoagulation Study Group

1 reference

12 December 2020

Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group

1 reference

12 December 2020

Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration

1 reference

12 December 2020

Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab

1 reference

12 December 2020

Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study

1 reference

12 December 2020

Bevacizumab in the treatment of colorectal cancer

1 reference

12 December 2020

Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results

1 reference

12 December 2020

Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy

1 reference

12 December 2020

Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows

1 reference

12 December 2020

The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing

1 reference

12 December 2020

Macular Epiretinal Brachytherapy in Treated Age-related Macular Degeneration

1 reference

12 December 2020

Spectral-Domain versus Time Domain Optical Coherence Tomography before and after Ranibizumab for Age-Related Macular Degeneration

1 reference

12 December 2020

Pneumatic displacement of submacular hemorrhage: safety, efficacy, and patient selection

1 reference

12 December 2020

Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial

1 reference

12 December 2020

10.1136/BJOPHTHALMOL-2014-305702

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

25136079

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25136079%20AND%20SRC:MED&resulttype=core&format=json